Amanda Carbonell

Selumetinib in Children with Inoperable Plexiform Neurofibromas

Andrea M. Gross, Pamela L. Wolters, Eva Dombi et al. · New England Journal of Medicine · 2020 · 698 citations · Full text

Medicine, Neurology, Pediatrics +9

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi et al. · Cancer Cell · 2023 · 107 citations · Full text

Life Sciences, Immunology, Oncology +16

Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity

Andrea M. Gross, Brittany Glassberg, Pamela L. Wolters et al. · Neuro-Oncology · 2022 · 65 citations · Full text

Medicine, Neurology, Pediatrics +17

The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

Sadhana Jackson, Eva H. Baker, Andrea M. Gross et al. · Neuro-Oncology Advances · 2020 · 36 citations · Full text

Medicine, Neurology, Oncology +17

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Geraldine O’Sullivan Coyne, Andrea M. Gross, Eva Dombi et al. · Journal of Clinical Oncology · 2020 · 24 citations

Medicine, Neurology, Pharmacology +15